
Kalohexis Unveils Dual MC3R/MC4R Agonist Data at ENDO 2026
Targeting both the MC3R and MC4R receptors may offer a more effective path to sustainable weight loss while bypassing the cardiovascular risks that have historically hampered obesity drug development. New data presented at the Endocrine Society’s annual meeting demonstrate that this dual-action approach preserves lean muscle mass in nonhuman primate models.



























